Erratum: Phase I Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53 (Clin Cancer Res (2021) 27 (5236-5247)DOI: 10.1158/1078-0432.CCR-21-0715)

Mansoor N. Saleh; Manish R. Patel; Todd M. Bauer; Sanjay Goel; Gerald S. Falchook; Geoffrey I. Shapiro; Ki Y. Chung; Jeffrey R. Infante; Robert M. Conry; Guilherme Rabinowits; David S. Hong; Judy S. Wang; Ulrich Steidl; Loren D. Walensky; Gurudatta Naik; Vincent Guerlavais; Vojislav Vukovic; D. Allen Annis; Manuel Aivado; Funda Meric-Bernstam

doi:10.1158/1078-0432.CCR-21-4241

Erratum: Phase I Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53 (Clin Cancer Res (2021) 27 (5236-5247)DOI: 10.1158/1078-0432.CCR-21-0715)

Mansoor N. Saleh
, Manish R. Patel
, Todd M. Bauer
, Sanjay Goel
, Gerald S. Falchook
, Geoffrey I. Shapiro
, Ki Y. Chung
, Jeffrey R. Infante
, Robert M. Conry
, Guilherme Rabinowits
, David S. Hong
, Judy S. Wang
, Ulrich Steidl
, Loren D. Walensky
, Gurudatta Naik
, Vincent Guerlavais
, Vojislav Vukovic
, D. Allen Annis
, Manuel Aivado
, Funda Meric-Bernstam

Clinical Research Unit (CRU)

Research output: Contribution to journal › Comment/debate

4 Citations (Scopus)

Abstract

In the original version of this article (1), author Loren D. Walensky is mistakenly omitted from the author list. This error has been corrected in the latest online HTML and PDF versions of the article and the authors’ contributions and disclosures have been updated as necessary. The authors regret this error.

Original language	English (US)
Pages (from-to)	429
Number of pages	1
Journal	Clinical Cancer Research
Volume	28
Issue number	2
DOIs	https://doi.org/10.1158/1078-0432.CCR-21-4241
Publication status	Published - 15 Jan 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1158/1078-0432.CCR-21-4241

Fingerprint

Dive into the research topics of 'Erratum: Phase I Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53 (Clin Cancer Res (2021) 27 (5236-5247)DOI: 10.1158/1078-0432.CCR-21-0715)'. Together they form a unique fingerprint.

Cite this

Saleh, M. N., Patel, M. R., Bauer, T. M., Goel, S., Falchook, G. S., Shapiro, G. I., Chung, K. Y., Infante, J. R., Conry, R. M., Rabinowits, G., Hong, D. S., Wang, J. S., Steidl, U., Walensky, L. D., Naik, G., Guerlavais, V., Vukovic, V., Annis, D. A., Aivado, M., & Meric-Bernstam, F. (2022). Erratum: Phase I Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53 (Clin Cancer Res (2021) 27 (5236-5247)DOI: 10.1158/1078-0432.CCR-21-0715). Clinical Cancer Research, 28(2), 429. https://doi.org/10.1158/1078-0432.CCR-21-4241

@article{d20a03c994e243c2974c6f32109708d5,

title = "Erratum: Phase I Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53 (Clin Cancer Res (2021) 27 (5236-5247)DOI: 10.1158/1078-0432.CCR-21-0715)",

abstract = "In the original version of this article (1), author Loren D. Walensky is mistakenly omitted from the author list. This error has been corrected in the latest online HTML and PDF versions of the article and the authors{\textquoteright} contributions and disclosures have been updated as necessary. The authors regret this error.",

author = "Saleh, \{Mansoor N.\} and Patel, \{Manish R.\} and Bauer, \{Todd M.\} and Sanjay Goel and Falchook, \{Gerald S.\} and Shapiro, \{Geoffrey I.\} and Chung, \{Ki Y.\} and Infante, \{Jeffrey R.\} and Conry, \{Robert M.\} and Guilherme Rabinowits and Hong, \{David S.\} and Wang, \{Judy S.\} and Ulrich Steidl and Walensky, \{Loren D.\} and Gurudatta Naik and Vincent Guerlavais and Vojislav Vukovic and Annis, \{D. Allen\} and Manuel Aivado and Funda Meric-Bernstam",

note = "Publisher Copyright: {\textcopyright} 2022 American Association for Cancer Research",

year = "2022",

month = jan,

day = "15",

doi = "10.1158/1078-0432.CCR-21-4241",

language = "English (US)",

volume = "28",

pages = "429",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "2",

}

Saleh, MN, Patel, MR, Bauer, TM, Goel, S, Falchook, GS, Shapiro, GI, Chung, KY, Infante, JR, Conry, RM, Rabinowits, G, Hong, DS, Wang, JS, Steidl, U, Walensky, LD, Naik, G, Guerlavais, V, Vukovic, V, Annis, DA, Aivado, M & Meric-Bernstam, F 2022, 'Erratum: Phase I Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53 (Clin Cancer Res (2021) 27 (5236-5247)DOI: 10.1158/1078-0432.CCR-21-0715)', Clinical Cancer Research, vol. 28, no. 2, pp. 429. https://doi.org/10.1158/1078-0432.CCR-21-4241

Erratum: Phase I Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53 (Clin Cancer Res (2021) 27 (5236-5247)DOI: 10.1158/1078-0432.CCR-21-0715). / Saleh, Mansoor N.; Patel, Manish R.; Bauer, Todd M. et al.
In: Clinical Cancer Research, Vol. 28, No. 2, 15.01.2022, p. 429.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Erratum

T2 - Phase I Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53 (Clin Cancer Res (2021) 27 (5236-5247)DOI: 10.1158/1078-0432.CCR-21-0715)

AU - Saleh, Mansoor N.

AU - Patel, Manish R.

AU - Bauer, Todd M.

AU - Goel, Sanjay

AU - Falchook, Gerald S.

AU - Shapiro, Geoffrey I.

AU - Chung, Ki Y.

AU - Infante, Jeffrey R.

AU - Conry, Robert M.

AU - Rabinowits, Guilherme

AU - Hong, David S.

AU - Wang, Judy S.

AU - Steidl, Ulrich

AU - Walensky, Loren D.

AU - Naik, Gurudatta

AU - Guerlavais, Vincent

AU - Vukovic, Vojislav

AU - Annis, D. Allen

AU - Aivado, Manuel

AU - Meric-Bernstam, Funda

PY - 2022/1/15

Y1 - 2022/1/15

N2 - In the original version of this article (1), author Loren D. Walensky is mistakenly omitted from the author list. This error has been corrected in the latest online HTML and PDF versions of the article and the authors’ contributions and disclosures have been updated as necessary. The authors regret this error.

AB - In the original version of this article (1), author Loren D. Walensky is mistakenly omitted from the author list. This error has been corrected in the latest online HTML and PDF versions of the article and the authors’ contributions and disclosures have been updated as necessary. The authors regret this error.

UR - https://www.scopus.com/pages/publications/85123658018

U2 - 10.1158/1078-0432.CCR-21-4241

DO - 10.1158/1078-0432.CCR-21-4241

M3 - Comment/debate

C2 - 35045962

AN - SCOPUS:85123658018

SN - 1078-0432

VL - 28

SP - 429

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 2

ER -

Erratum: Phase I Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53 (Clin Cancer Res (2021) 27 (5236-5247)DOI: 10.1158/1078-0432.CCR-21-0715)

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this